bioAffinity Technologies (BIAF) and Its Peers Head to Head Survey

bioAffinity Technologies (NASDAQ:BIAF) is one of 38 public companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare bioAffinity Technologies to related companies based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, risk and valuation.

Volatility and Risk

bioAffinity Technologies has a beta of 3.93, suggesting that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ peers have a beta of 6.20, suggesting that their average stock price is 520% more volatile than the S&P 500.

Profitability

This table compares bioAffinity Technologies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-2,244.15%	-80.82%	-69.38%
bioAffinity Technologies Competitors	-359.08%	-18.73%	-11.46%

Earnings and Valuation

This table compares bioAffinity Technologies and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$8.15 million	-2.99
bioAffinity Technologies Competitors	$1.35 billion	$85.98 million	-4.49

bioAffinity Technologies’ peers have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations and price targets for bioAffinity Technologies and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	45	724	1146	26	2.59

As a group, “Commercial physical research” companies have a potential upside of 4.59%. Given bioAffinity Technologies’ peers higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its peers.

Institutional and Insider Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 50.9% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 15.9% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

bioAffinity Technologies peers beat bioAffinity Technologies on 8 of the 10 factors compared.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.